all depends on the trial results which should flow in by end of year for HerVaxx and sometimes between 4th quarter 2020 and 2nd quarter 2021 for CF 33 and maybe PD1-Vaxx. Plus the " mysterial " B-Vaxx with a ph2 update at anytime.
So, if Her-Vaxx delivers as expected it will open the doors for IMU as B-cell tech will become the new cutting edge tech and the pharma world will assume that PD1 and whatever comes next will perform as well. Same applies to CF33, once proven to be the next OV generation - the pharma universe is the limit.
Therefore, we could hope for a " launch " by end of the year / early 2021.
Unless some drugs being bought out / IMU taken over before that.
All in my opinion of course.
GLTA
IMU Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)